Huang et al. [72] from Peking University established the G‐CSF/ATG‐based protocol, which includes unmanipulated G/CSF‐primed bone marrow (BM) and peripheral blood (PB) grafts; administration of ATG to recipients; and cyclosporine, mycophenolate mofetil, methotrexate for GVHD prophylaxis [20, 73]. Here, CSF3 is linked to graft versus host disease.